Dual role of sphingosine kinase-1 in promoting the differentiation of dermal fibroblasts and the dissemination of melanoma cells

Oncogene

Volumn 33, Issue 26, 2014, Pages 3364-3373

  Albinet, V ^a,b   Bats, M L ^a,b   Huwiler, A ^c   Rochaix, P ^d   Chevreau, C ^e   Segui B ^a,b   Levade, T ^a,b,f   Andrieu Abadie, N ^a,b  

^a CHU RANGUEIL   (France)

^b UNIVERSITÉ PAUL SABATIER   (France)

^c UNIVERSITY OF BERN   (Switzerland)

^d Service d'Anatomie et de Cytologie Pathologiques   (France)

^e INSTITUT CLAUDIUS REGAUD   (France)

^f TOULOUSE UNIVERSITY HOSPITAL   (France)

Author keywords

dermal fibroblasts; melanoma; migration; sphingosine 1 phosphate

Indexed keywords

MATRIX METALLOPROTEINASE; MITOGEN ACTIVATED PROTEIN KINASE; SPHINGOSINE 1 PHOSPHATE; SPHINGOSINE KINASE 1; B RAF KINASE; BRAF PROTEIN, HUMAN; GELATINASE A; GELATINASE B; GUANOSINE TRIPHOSPHATASE; LYASE; LYSOPHOSPHOLIPID; MEMBRANE PROTEIN; MESSENGER RNA; MMP2 PROTEIN, HUMAN; MMP9 PROTEIN, HUMAN; NRAS PROTEIN, HUMAN; PHOSPHOTRANSFERASE; SMALL INTERFERING RNA; SPHINGOSINE; SPHINGOSINE 1-PHOSPHATE; SPHINGOSINE 1-PHOSPHATE LYASE (ALDOLASE); SPHINGOSINE KINASE;

ANIMAL CELL; ARTICLE; BRAF GENE; CANCER GROWTH; CARCINOGENESIS; CELL COMMUNICATION; CELL DIFFERENTIATION; CELL MIGRATION; CONTROLLED STUDY; ENZYME ACTIVATION; GENE MUTATION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; MELANOMA; MELANOMA CELL LINE; MOUSE; MYOFIBROBLAST; NEVUS; NONHUMAN; ONCOGENE; ONCOGENE N RAS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SKIN FIBROBLAST; TRANSCRIPTOMICS; TUMOR MICROENVIRONMENT; ANALOGS AND DERIVATIVES; ANIMAL; BIOSYNTHESIS; C57BL MOUSE; CELL MOTION; CELL TRANSFORMATION; ENZYMOLOGY; FEMALE; FIBROBLAST; GENE EXPRESSION PROFILING; GENETICS; HEK293 CELL LINE; KNOCKOUT MOUSE; METABOLISM; PATHOLOGY; RNA INTERFERENCE; SKIN TUMOR;

MUS;

ALDEHYDE-LYASES; ANIMALS; CELL COMMUNICATION; CELL DIFFERENTIATION; CELL MOVEMENT; CELL TRANSFORMATION, NEOPLASTIC; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; FIBROBLASTS; GENE EXPRESSION PROFILING; GTP PHOSPHOHYDROLASES; HEK293 CELLS; HUMANS; LYSOPHOSPHOLIPIDS; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MELANOMA; MEMBRANE PROTEINS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MYOFIBROBLASTS; PHOSPHOTRANSFERASES (ALCOHOL GROUP ACCEPTOR); PROTO-ONCOGENE PROTEINS B-RAF; RNA INTERFERENCE; RNA, MESSENGER; RNA, SMALL INTERFERING; SKIN NEOPLASMS; SPHINGOSINE;

EID: 84903594166     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2013.303     Document Type: Article

References (54)

1. De Wever O, Mareel M. Role of tissue stroma in cancer cell invasion. J Pathol 2003; 200: 429-447.
2. Kalluri R, Zeisberg M. Fibroblasts in cancer. Nat Rev Cancer 2006; 6: 392-401.
3. Cirri P, Chiarugi P. Cancer-associated-fibroblasts and tumour cells: a diabolic liaison driving cancer progression. Cancer Metastasis Rev 2011; 31: 195-208.
4. Joyce JA, Pollard JW. Microenvironmental regulation of metastasis. Nat Rev Cancer 2009; 9: 239-252.
5. Kunz-Schughart LA, Knuechel R. Tumor-associated fibroblasts (part I): active stromal participants in tumor development and progression? Histol Histopathol 2002; 17: 599-621.
6. Geller AC, Swetter SM, Brooks K, Demierre MF, Yaroch AL. Screening, early detection, and trends for melanoma: current status (2000-2006) and future directions. J Am Acad Dermatol 2007; 57: 555-572.
7. Ruiter D, Bogenrieder T, Elder D, Herlyn M. Melanoma-stroma interactions: structural and functional aspects. Lancet Oncol 2002; 3: 35-43.
8. Shimoda M, Mellody KT, Orimo A. Carcinoma-associated fibroblasts are a ratelimiting determinant for tumour progression. Semin Cell Dev Biol 2010; 21: 19-25.
9. Clark Jr WH, Elder DE, Dt Guerry, Braitman LE, Trock BJ, Schultz D et al. Model predicting survival in stage I melanoma based on tumor progression. J Natl Cancer Inst 1989; 81: 1893-1904.
10. Breslow A. Thickness, cross-sectional areas and depth invasion in the prognosis of cutaneous melanoma. Ann Surg 1970; 172: 902-908.
11. Smalley KS, Lioni M, Herlyn M. Targeting the stromal fibroblasts: a novel approach to melanoma therapy. Expert Rev Anticancer Ther 2005; 5: 1069-1078.
12. Flach EH, Rebecca VW, Herlyn M, Smalley KS, Anderson AR. Fibroblasts contribute to melanoma tumor growth and drug resistance. Mol Pharm 2011; 8: 2039-2049.
13. Colie S, Van Veldhoven PP, Kedjouar B, Bedia C, Albinet V, Sorli SC et al. Disruption of sphingosine 1-phosphate lyase confers resistance to chemotherapy and promotes oncogenesis through Bcl-2/Bcl-xL upregulation. Cancer Res 2009; 69: 9346-9353.
14. Huwiler A, Pfeilschifter J. New players on the center stage: sphingosine 1-phosphate and its receptors as drug targets. Biochem Pharmacol 2008; 75: 1893-1900.
15. Maceyka M, Harikumar KB, Milstien S, Spiegel S. Sphingosine-1-phosphate signaling and its role in disease. Trends Cell Biol 2012; 22: 50-60.
16. Rolin J, Maghazachi AA. Effects of lysophospholipids on tumor microenvironment. Cancer Microenviron 2011; 4: 393-403.
17. LaMontagne K, Littlewood-Evans A, Schnell C, O'Reilly T, Wyder L, Sanchez T et al. Antagonism of sphingosine-1-phosphate receptors by FTY720 inhibits angiogenesis and tumor vascularization. Cancer Res 2006; 66: 221-231.
18. Visentin B, Vekich JA, Sibbald BJ, Cavalli AL, Moreno KM, Matteo RG et al. Validation of an anti-sphingosine-1-phosphate antibody as a potential therapeutic in reducing growth, invasion, and angiogenesis in multiple tumor lineages. Cancer Cell 2006; 9: 225-238.
19. Caballero S, Swaney J, Moreno K, Afzal A, Kielczewski J, Stoller G et al. Anti-sphingosine-1-phosphate monoclonal antibodies inhibit angiogenesis and sub-retinal fibrosis in a murine model of laser-induced choroidal neovascularization. Exp Eye Res 2009; 88: 367-377.
20. Takuwa Y, Ikeda H, Okamoto Y, Takuwa N, Yoshioka K. Sphingosine-1- phosphate as a mediator involved in development of fibrotic diseases. Biochim Biophys Acta 2012; 1831: 185-192.
21. Dvorak HF. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med 1986; 315: 1650-1659.
22. Rebecca VW, Sondak VK, Smalley KS. A brief history of melanoma: from mummies to mutations. Melanoma Res 2012; 22: 114-122.
23. Li G, Satyamoorthy K, Meier F, Berking C, Bogenrieder T, Herlyn M. Function and regulation of melanoma-stromal fibroblast interactions: when seeds meet soil. Oncogene 2003; 22: 3162-3171.
24. Beacham DA, Cukierman E. Stromagenesis: the changing face of fibroblastic microenvironments during tumor progression. Semin Cancer Biol 2005; 15: 329-341.
25. Hofmann UB, Houben R, Brocker EB, Becker JC. Role of matrix metalloproteinases in melanoma cell invasion. Biochimie 2005; 87: 307-314.
26. Liu SQ, Huang JA, Qin MB, Su YJ, Lai MY, Jiang HX et al. Sphingosine kinase 1 enhances colon cancer cell proliferation and invasion by upregulating the production of MMP-2/9 and uPA via MAPK pathways. Int J Colorectal Dis 2012; 27: 1569-1578.
27. French KJ, Schrecengost RS, Lee BD, Zhuang Y, Smith SN, Eberly JL et al. Discovery and evaluation of inhibitors of human sphingosine kinase. Cancer Res 2003; 63: 5962-5969.
28. Platz A, Egyhazi S, Ringborg U, Hansson J. Human cutaneous melanoma; a review of NRAS and BRAF mutation frequencies in relation to histogenetic subclass and body site. Mol Oncol 2008; 1: 395-405.
29. Xia P, Gamble JR, Wang L, Pitson SM, Moretti PA, Wattenberg BW et al. An oncogenic role of sphingosine kinase. Curr Biol 2000; 10: 1527-1530.
30. Gault CR, Eblen ST, Neumann CA, Hannun YA, Obeid LM. Oncogenic K-Ras regulates bioactive sphingolipids in a sphingosine kinase 1-dependent manner. J Biol Chem 2012; 287: 31794-31803.
31. Madhunapantula SV, Hengst J, Gowda R, Fox TE, Yun JK, Robertson GP. Targeting sphingosine kinase-1 to inhibit melanoma. Pigment Cell Melanoma Res 2012; 25: 259-274.
32. Bektas M, Jolly PS, Muller C, Eberle J, Spiegel S, Geilen CC. Sphingosine kinase activity counteracts ceramide-mediated cell death in human melanoma cells: role of Bcl-2 expression. Oncogene 2005; 24: 178-187.
33. Yamanaka M, Shegogue D, Pei H, Bu S, Bielawska A, Bielawski J et al. Sphingosine kinase 1 (SPHK1) is induced by transforming growth factor-beta and mediates TIMP-1 up-regulation. J Biol Chem 2004; 279: 53994-54001.
34. Gellings Lowe N, Swaney JS, Moreno KM, Sabbadini RA. Sphingosine-1- phosphate and sphingosine kinase are critical for transforming growth factor-betastimulated collagen production by cardiac fibroblasts. Cardiovasc Res 2009; 82: 303-312.
35. Kono Y, Nishiuma T, Nishimura Y, Kotani Y, Okada T, Nakamura S et al. Sphingosine kinase 1 regulates differentiation of human and mouse lung fibroblasts mediated by TGF-beta1. Am J Resp Cell Mol Biol 2007; 37: 395-404.
36. Watterson KR, Lanning DA, Diegelmann RF, Spiegel S. Regulation of fibroblast functions by lysophospholipid mediators: potential roles in wound healing. Wound Repair Regen 2007; 15: 607-616.
37. Pyne NJ, Dubois G, Pyne S. Role of sphingosine 1-phosphate and lysophosphatidic acid in fibrosis. Biochim Biophys Acta 2012; 1831: 228-238.
38. Schwalm S, Pfeilschifter J, Huwiler A. Sphingosine-1-phosphate: a Janus-faced mediator of fibrotic diseases. Biochim Biophys Acta 2013; 1831: 239-250.
39. Urata Y, Nishimura Y, Hirase T, Yokoyama M. Sphingosine 1-phosphate induces alpha-smooth muscle actin expression in lung fibroblasts via Rho-kinase. Kobe J Med Sci 2005; 51: 17-27.
40. Youm JK, Jo H, Hong JH, Shin DM, Kwon MJ, Jeong SK et al. K6PC-5, a sphingosine kinase activator, induces anti-aging effects in intrinsically aged skin through intracellular Ca2+ signaling. J Dermatol Sci 2008; 51: 89-102.
41. Li C, Zheng S, You H, Liu X, Lin M, Yang L et al. Sphingosine 1-phosphate (S1P)/S1P receptors are involved in human liver fibrosis by action on hepatic myofibroblasts motility. J Hepatol 2011; 54: 1205-1213.
42. Keller CD, Rivera Gil P, Tolle M, van der Giet M, Chun J, Radeke HH et al. Immunomodulator FTY720 induces myofibroblast differentiation via the lysophospholipid receptor S1P3 and Smad3 signaling. Am J Pathol 2007; 170: 281-292.
43. Yin M, Soikkeli J, Jahkola T, Virolainen S, Saksela O, Holtta E. TGF-beta signaling, activated stromal fibroblasts, and cysteine cathepsins B and L drive the invasive growth of human melanoma cells. Am J Pathol 2012; 181: 2202-2216.
44. Jolly PS, Bektas M, Watterson KR, Sankala H, Payne SG, Milstien S et al. Expression of SphK1 impairs degranulation and motility of RBL-2H3 mast cells by desensitizing S1P receptors. Blood 2005; 105: 4736-4742.
45. Yamaguchi H, Kitayama J, Takuwa N, Arikawa K, Inoki I, Takehara K et al. Sphingosine-1-phosphate receptor subtype-specific positive and negative regulation of Rac and haematogenous metastasis of melanoma cells. Biochem J 2003; 374: 715-722.
46. Arikawa K, Takuwa N, Yamaguchi H, Sugimoto N, Kitayama J, Nagawa H et al. Ligand-dependent inhibition of B16 melanoma cell migration and invasion via endogenous S1P2 G protein-coupled receptor. Requirement of inhibition of cellular RAC activity. J Biol Chem 2003; 278: 32841-32851.
47. Ponnusamy S, Selvam SP, Mehrotra S, Kawamori T, Snider AJ, Obeid LM et al. Communication between host organism and cancer cells is transduced by systemic sphingosine kinase 1/sphingosine 1-phosphate signalling to regulate tumour metastasis. EMBO Mol Med 2012; 4: 761-775.
48. Deng J, Liu Y, Lee H, Herrmann A, Zhang W, Zhang C et al. S1PR1-STAT3 signaling is crucial for myeloid cell colonization at future metastatic sites. Cancer Cell 2012; 21: 642-654.
49. Sly WS, Grubb J. Isolation of fibroblasts from patients. Methods Enzymol 1979; 58: 444-450.
50. Lavieu G, Scarlatti F, Sala G, Carpentier S, Levade T, Ghidoni R et al. Sphingolipids in macroautophagy. Methods Mol Biol 2008; 445: 159-173.
51. Mitra P, Payne SG, Milstien S, Spiegel S. A rapid and sensitive method to measure secretion of sphingosine-1-phosphate. Methods Enzymol 2007; 434: 257-264.
52. Pushparaj PN, Manikandan J, Tay HK, H'Ng S C, Kumar SD, Pfeilschifter J et al. Sphingosine kinase 1 is pivotal for Fc epsilon RI-mediated mast cell signaling and functional responses in vitro and in vivo. J Immunol 2009; 183: 221-227.
53. Vasseur S, Hoffmeister A, Garcia S, Bagnis C, Dagorn JC, Iovanna JL. P8 is critical for tumour development induced by rasV12 mutated protein and E1A oncogene. EMBO Rep 2002; 3: 165-170.
54. Asnacios A, Courbon F, Rochaix P, Bauvin E, Cances-Lauwers V, Susini C et al. Indium-111-pentetreotide scintigraphy and somatostatin receptor subtype 2 expression: new prognostic factors for malignant well-differentiated endocrine tumors. J Clin Oncol 2008; 26: 963-970.